APEIRON Biologics AG Collaborates with Idis Ltd to Initiate Managed Access Program

Apeiron today announced that it has retained the services of Idis Ltd to initiate a Managed Access Program for its product APN311 (ch14.18/CHO), for patients with high-risk neuroblastoma. The program will run in specified countries throughout the world and is expected to be initiated in Q4 2013.

Press release